Press release
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size in the 7MM was ~USD 1,300 Million in 2023, estimated DelveInsight
DelveInsight's "Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Psychosis in Parkinson's and Alzheimer's Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson's and Alzheimer's Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Psychosis in Parkinson's and Alzheimer's Disease Market by downloading the comprehensive report from DelveInsight @ Psychosis in Parkinson's and Alzheimer's Disease Market [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Psychosis in Parkinson's and Alzheimer's Disease Market Report
* As per DelveInsight analysis, it is estimated that the Psychosis in Parkinson's and Alzheimer's Disease treatment market will experience significant changes during the forecast period of 2024-2034, owing to the launch of new therapies that are in clinical development for its treatment and due to the increasing patient pool.
* As per DelveInsight analysis, in 2023, there were approximately 15.4 million diagnosed prevalent cases of Alzheimer's disease in the 7MM. Out of these, the US accounted for approximately 41% of the total cases, while, the EU4 and the UK accounted for the least with nearly 33% of the total, in 2023.
* As per DelveInsight analysis, there were approximately 6 million total diagnosed prevalent cases of psychosis in Alzheimer's disease, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
* As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Parkinson's Disease Psychosis in the 7MM were approximately 876 thousand cases. These cases are projected to increase during the forecast period (2024-2034).
* The leading Psychosis in Parkinson's and Alzheimer's Disease Companies such as ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Promising Psychosis in Parkinson's and Alzheimer's Disease Therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
Gain a competitive edge in the Psychosis in Parkinson's and Alzheimer's Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Psychosis in Parkinson's and Alzheimer's Disease Treatment Drugs [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psychosis in Parkinson's and Alzheimer's Disease Epidemiology Segmentation in the 7MM
* Psychosis in Parkinson's and Alzheimer's Disease Diagnosed Prevalent Cases
* Psychosis in Parkinson's and Alzheimer's Disease Gender-specific Cases
* Psychosis in Parkinson's and Alzheimer's Disease Age-specific Cases
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market
The current treatment regime involves nonpharmacological and pharmacological approaches. The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. The use of typical and atypical antipsychotics are the first-line treatment (e.g., aripiprazole, clozapine, quetiapine, etc.). However, atypical antipsychotics are often considered in the initial therapy, which reduces the risk of later deterioration in patients. Apart from antipsychotics, 5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), or other antidepressants are also used.
Discover key developments and opportunities in the Psychosis in Parkinson's and Alzheimer's Disease Market. Click here to learn more from DelveInsight's latest report @ Psychosis in Parkinson's and Alzheimer's Disease Market Size [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psychosis in Parkinson's and Alzheimer's Disease Market Insights
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Psychosis in Parkinson's and Alzheimer's Disease Marketed Drugs
* NUPLAZID (pimavanserin): Acadia Pharmaceuticals
Psychosis in Parkinson's and Alzheimer's Disease Emerging Drugs
* Ulotaront (SEP-363856): Sunovion Pharmaceuticals
* KarXT (xanomeline-trospium): Karuna Therapeutics
* ITI-1284: Intra-Cellular Therapies
Psychosis in Parkinson's and Alzheimer's Disease Market Outlook
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Download DelveInsight's Psychosis in Parkinson's and Alzheimer's Disease Market report today and stay ahead in this rapidly evolving field. @ Psychosis in Parkinson's and Alzheimer's Disease Clinical Trials [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Psychosis in Parkinson's and Alzheimer's Disease Market Report
* Coverage- 7MM
* Psychosis in Parkinson's and Alzheimer's Disease Companies- ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Psychosis in Parkinson's and Alzheimer's Disease Therapies- NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
* Psychosis in Parkinson's and Alzheimer's Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Psychosis in Parkinson's and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement
Download the report to understand which factors are driving Psychosis in Parkinson's and Alzheimer's Disease Market Trends @ Psychosis in Parkinson's and Alzheimer's Disease Market Trends [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Psychosis in PD and AD Market Overview at a Glance
4. Methodology of Psychosis in Parkinson's disease and Alzheimer's disease Epidemiology and Market
5. Executive Summary of Psychosis in Parkinson's disease and Alzheimer's disease
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Psychosis in Parkinson's disease and Alzheimer's disease: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psychosis-in-parkinsons-and-alzheimers-disease-treatment-market-size-in-the-7mm-was-usd-1300-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size in the 7MM was ~USD 1,300 Million in 2023, estimated DelveInsight here
News-ID: 3666596 • Views: …
More Releases from ABNewswire
Giorgia Fumanti Releases New Duet "I Have A Dream" With South African Singer Sel …
Giorgia Fumanti has teamed up with South African classical-pop artist Selim Kagee for a soaring duet "I Have A Dream." The song is both inspirational and hopeful in its message to humanity.
Conjuring some of Martin Luther King's own optimism from his famous "I Have A Dream" speech, the song expresses a desire for peace and love across the globe. The song is accompanied by a beautifully shot video, with Fumanti…
Referral Lab Joins Southern Academy of Perio as Corporate Advisory Board Member
Referral Lab, a leader in Dental Specialist Analytics, has been appointed as a Corporate Advisory Board Member of the Southern Academy of Periodontology (SAP). This strategic collaboration aims to enhance the use of advanced referral tracking technologies in dental practices throughout the southern United States.
As a Corporate Advisory Board Member, Referral Lab will work closely with the SAP to share insights and provide guidance on how cutting-edge analytics software can…
Guard Recruiter: The New Premier Job Board and Staffing Firm for Security Profes …
Atlanta, GA - Guard Recruiter [http://www.guardrecruiterpro.com/], an innovative job board and staffing firm exclusively for the security industry, proudly announces its official launch. Guard Recruiter provides a dedicated platform for security professionals seeking new career opportunities and companies in need of qualified security personnel. Designed to meet the ever-growing demand for reliable security services, Guard Recruiter streamlines the recruitment process, creating a powerful connection between top talent and businesses requiring…
The Heat Wave Crisis: How India Is Coping with Record Temperatures and Health Ri …
The article is authored by Dr. Manu Gupta, the Head of the Sustainable Environment and Ecological Development Society (SEEDS)
Image: https://www.abnewswire.com/uploads/60d8d553f5cc05c1f80d66b5ec412fcb.jpg
India faced an unprecedented surge in extreme heat waves this summer, impacting millions nationwide, which is very likely to cause a humanitarian crisis. The capital city, Delhi, experienced record-breaking temperatures, soaring nearly 50 degrees C on May 29, leading to widespread distress and discomfort. According to India's Union Ministry of Health,…
More Releases for Alzheimer
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Alzheimer Diagnostic Tests Market
GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
